Difficulty: Medium
Average Score: 90%
Practice
What is the main site of distribution for infliximab?
Correct answer
A
Rationale
Infliximab is a monoclonal antibody used to treat inflammatory conditions like rheumatoid arthritis and Crohn's disease. The main site of distribution for infliximab is in fat tissue. This is because infliximab is a large molecule that has a high affinity for binding to proteins in fat tissue, allowing it to be stored there for longer periods.
Option A is correct because fat tissue serves as a reservoir for infliximab, enabling a slow release into the bloodstream over time. This prolonged release helps maintain therapeutic levels of the drug in the body.
Options B, C, and D are incorrect because infliximab is not primarily distributed in plasma, extracellular fluids, or cell cytosol. While these compartments may play a role in the metabolism or elimination of the drug, they are not the main sites of distribution for infliximab.
Understanding the site of distribution of drugs like infliximab is crucial for healthcare professionals to optimize dosing regimens and ensure effective treatment outcomes for patients. By knowing that infliximab is mainly distributed in fat tissue, clinicians can adjust dosing schedules accordingly to maintain therapeutic levels in the body.
Option A is correct because fat tissue serves as a reservoir for infliximab, enabling a slow release into the bloodstream over time. This prolonged release helps maintain therapeutic levels of the drug in the body.
Options B, C, and D are incorrect because infliximab is not primarily distributed in plasma, extracellular fluids, or cell cytosol. While these compartments may play a role in the metabolism or elimination of the drug, they are not the main sites of distribution for infliximab.
Understanding the site of distribution of drugs like infliximab is crucial for healthcare professionals to optimize dosing regimens and ensure effective treatment outcomes for patients. By knowing that infliximab is mainly distributed in fat tissue, clinicians can adjust dosing schedules accordingly to maintain therapeutic levels in the body.